Rockwell Medical, Inc.

Thank you for your patience and please continue to hold. Thank you for standing by. And welcome to the Rockwell Medical first quarter 2021 results call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference may be recorded. Should you require any further assistance, please press star 0. I would now like to hand the conference over to your host, Claudia Steislinger, Investor Relations.

Good afternoon. This is Claudia Steislinger of Argo Partners, the investor relations representative for Rockwell Medical. Joining me from Rockwell Medical on today's call are Dr. Russell Ellison, President and Chief Executive Officer, and Russell Skipstead, Executive Vice President, Chief Financial Officer, and Chief Business Officer. Dr. Mark Hoffman, Chief Medical Officer, and Tim Cole, Senior Vice President of Sales and Marketing, will be available for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company within the meaning of the federal securities laws, including but not limited to the types of statements identified as forward-looking in our quarterly report on Form 10-Q that was filed today, our annual report on Form 10-K that was filed on March 31, 2021, and our subsequent periodic reports filed with the SEC which will all be available on our website in the investor relations section. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC. This conference call can be accessed on Rockwell Medical's Investor Relations webpage. This call is being recorded on May 17, 2021 for audio rebroadcast and can also be accessed on the same webpage. At this time, I would like to turn the conference call over to Rockwell Medical's Chief Executive Officer, Dr. Russell Ellison. Russell?

Good afternoon, and thank you for joining us. Since it has only been about six weeks since our last earnings call where we detailed for you our strategy, we will keep this call short. In the first quarter of 2021, we continue to execute against our strategy to accelerate growth by combining the solid foundation, strength, and reputation of our dialysis business with what we believe are the high growth potential of therapeutics generated from our FPC platform in multiple disease states. Our dialysis business, the base of which is the sales of concentrates, continue to steadily perform. We are the second largest supplier of hemodialysis concentrates in the United States, and this business generates about 60 million in annual revenue and gives us a solid foundation on which to grow. Our net sales for Triferic in the U.S. dialysis market were lower in Q1 compared to the fourth quarter of 2020. While the net number of contracted clinics increased, three clinics that were Triferic customers had to discontinue use due to acquisition or management changes. The number of clinics actively treating patients was flat quarter over quarter. Q4 2020 was our strongest period of sales to date. We went under contract with three new independent dialysis organizations, each of which made large purchases in preparation for a Q1 implementation. However, there were delays in implementation in all three cases, and repurchases did not occur in Q1. We are expecting to see reorders from some of these clinics in Q2 as they begin ramping up and putting patients on therapy. Triferic Avenue, our IV formulation of triferic, was commercially launched in February. As we have said before, we expect a slower uptake as clinics have found it difficult to accommodate the labor requirement of delivering a slow IV infusion at each dialysis session. We are actively exploring alternative administration methods, and we expect to have options to present to customers later this year. Despite the challenges we have faced with Triferic in the cost-conscious capitated payment environment of dialysis, We continue to make progress, and we believe adoption will increase going forward as more of our real-world data read out in the second half. The clinics that utilize Triferic are seeing positive results, stable hemoglobin, reduced interventions with other IV anemia drugs, and the resulting cost savings. Our customers are loyal as a result, and many are helping us generate the real-world evidence that we expect will be critical to our future success. To date, more than 1.3 million doses have been given in the frail hemodialysis patient population, which has generated extensive safety and efficacy data for our FPC technology. These data are foundational as we pivot Rockwell Medical to growth by developing pharmaceutical products that are based on our FPC platform for disease states outside of dialysis. Today, I'll focus my remaining comments on the FPC home infusion program. a major catalyst, and potentially a very large growth opportunity. Our decision to select home infusion as our priority development area is a strategic one. A safe and effective treatment for iron deficiency anemia is a significant unmet need for patients receiving intravenous therapies at home. As more and more patients are being treated in the home, we believe that need will intensify. We believe the excellent safety and reliable efficacy of the FPC molecule make it an ideal candidate for treating these patients. Based on my 30-plus years of experience in drug development, I believe our experience with FPC significantly de-risks its clinical development for use in the home infusion setting. Based on the safety and efficacy data we have seen to date from its use in the dialysis setting, Typically in clinical trials, you're trying to learn about the effectiveness of your product, and you're assessing its safety in the patient population that you're studying. With FPC, we're fortunate to have a large safety database of more than a million doses given to dialysis patients with no serious safety events. So we believe the risk of an unexpected safety issue is significantly reduced. And regarding efficacy, we know that FPC can improve iron deficiency anemia no matter the underlying cause. as long as the patient is not actively bleeding. This is not the case with respect to the older IV iron products where the effect of the dose you give is very much influenced by the patient's condition and disease state, particularly by the presence of inflammation. This means that the ability to demonstrate the safety and efficacy of FPC for use in the home infusion setting is substantially de-risked compared to most other drugs in Phase II trials. The growth of home infusion is accelerating. driven by new technologies that allow for therapies to be safely given in the home setting. Likewise, there is a growing number of treatments that are being given in the home setting for an increasing number of diseases. Cost-saving is another driver of growth in the home infusion setting. It's expensive to give long intravenous infusions in a clinic or a hospital setting. Both private health insurers and Medicare have favorable reimbursement policies for home infusions. Many patient groups requiring home infusion therapies suffer from chronic diseases that are associated with a high incidence of iron deficiency and anemia. Importantly, most physicians who are prescribing nutrients or medicines for home infusion do not generally have practices set up for the IV infusions required for the other forms of parenteral iron, and frequent office visits can be difficult for home infusion patients. This results in a vicious cycle of underdiagnosis and undertreatment of iron deficiency. For example, in the home parenteral nutrition population, half of patients remain iron deficient. Contrast this with the dialysis population, which is also at high risk for iron deficiency anemia, where less than 6% of patients have iron deficiency at any point. And it's important to note the consequences of iron deficiency can be serious if left untreated. including an increased risk of extreme fatigue, immune function compromise, and heart failure. Home infusion has the potential to be a much higher margin business than our FPC product portfolio and dialysis, as we believe that the future FPC-based product would meet the criteria for Medicare Part B and commercial insurance, and thus would be well positioned for diverse, private, and public reimbursement. The FDA has confirmed that our proposed FPC treatment for IDA and home infusion setting will be a 505 submission. This means that we would submit a new drug application for the home infusion product, which, if approved, may then be eligible for public and private reimbursement, separate and distinct from the current products for dialysis, allowing for appropriate pricing. With the ability to secure appropriate pricing and considering the suitability of the product in this area, we estimate total addressable market opportunity in the U.S. of up to $600 million. We expect to have our pre-IMD meeting with the FDA and pending a successful outcome to shortly thereafter start our Phase II trial later this year. This trial will be the first well-controlled randomized clinical trial of any iron product for the treatment of anemia in patients undergoing home infusion. I look forward to updating you as we progress. With that, I'll turn the call to Russell Skipstead for a brief financial overview. Russell?